BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Global Liver Institute - ECPv6.17.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Global Liver Institute
X-ORIGINAL-URL:https://globalliver.org
X-WR-CALDESC:Events for Global Liver Institute
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20280312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20281105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270116
DTEND;VALUE=DATE:20270118
DTSTAMP:20261027T192416Z
CREATED:20261027T192416Z
LAST-MODIFIED:20261027T192416Z
UID:1480-1800057600-1800230399@globalliver.org
SUMMARY:GMHA Impact House and the 11th Dialogues in Diabetes & Metabolism - India
DESCRIPTION:A global platform bringing together policymakers\, clinicians\, researchers and industry leaders to shape solutions for metabolic health challenges in India and beyond.
URL:https://globalliver.org/event/gmha-impact-house-and-the-11th-dialogues-in-diabetes-metabolism-india/
CATEGORIES:Partner Event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270213
DTSTAMP:20261027T192526Z
CREATED:20261027T192526Z
LAST-MODIFIED:20261027T192526Z
UID:1482-1802217600-1802476799@globalliver.org
SUMMARY:NHC Health Leadership Conference - Savannah\, GA
DESCRIPTION:After two years in Fort Lauderdale\, the National Health Council’s signature leadership convening is heading to Savannah for the first time. From Feb. 10–12\, 2027\, CEOs\, executive directors\, board leaders\, and senior executives will come together for candid conversation\, peer learning\, and practical insight on the challenges shaping their organizations and the patients they serve.  \nAbout the Event\nLeading a nonprofit health organization requires navigating a changing policy environment\, funding pressures\, evolving technology\, public expectations\, and persistent barriers that make care harder for patients to access and afford. HLC gives senior leaders dedicated time to work through these challenges with peers and experts.  \nOver three days\, programming will address organizational leadership and governance\, policy and advocacy\, strategic communications\, innovation and technology\, nonprofit growth and sustainability\, and other priorities facing patient organizations and nonprofit health groups.  \nAs the NHC advances We Are All Patients: The Human Cost of a Broken System\, the conference will also examine how strong organizations and stronger collaboration can help reduce the financial and systemic barriers that stand between patients and care.  \nWhat Attendees Will Gain \n\n\n\nPractical insight on the leadership\, policy\, and organizational challenges facing patient organizations and nonprofit health groups.\nCandid exchange with peers who understand the responsibilities of mission-driven leadership.\nGuidance to help align organizational strategy with the changing needs of patients and caregivers.\nNew relationships and opportunities to increase individual and collective impact across the patient community. \n\n\n\nWho Should Attend\nThe conference is an exclusive benefit for senior leaders from NHC member Patient Organizations and Partners of Patient Organizations.  \n\n\n\nCEOs and executive directors: Leaders responsible for organizational strategy\, mission\, policy engagement\, and innovation.\nBoard leaders: Board chairs\, vice chairs\, and other senior board members guiding mission-driven organizations. The NHC encourages CEOs and executive directors to attend with a board leader when possible.\nSenior executives: COOs\, CFOs\, chief strategy officers\, communications and policy executives\, and other senior leaders responsible for organizational direction and impact. \n\n\n\nSponsorship and Industry Participation\nNHC Business & Industry members and eligible non-member for-profit organizations may participate through event sponsorship. Sponsorship offers an opportunity to connect with patient organization leaders and better understand the priorities shaping their work.  \nQuestions?\nFor questions regarding registration or event logistics\, please contact the NHC’s Senior Director of Meetings & Events\, Racquel Codling. For programming questions\, please contact NHC’s Director of Membership\, Lindsay Marcal. For sponsorship information\, please contact Randall Rutta.
URL:https://globalliver.org/event/nhc-health-leadership-conference-savannah-ga/
CATEGORIES:Partner Event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270214
DTSTAMP:20261027T192626Z
CREATED:20261027T192626Z
LAST-MODIFIED:20261027T192626Z
UID:1484-1802217600-1802563199@globalliver.org
SUMMARY:EASL Steatotic Liver Disease Summit 2027 - Berlin
DESCRIPTION:The EASL Steatotic Liver Disease Summit 2027 comprises two complementary parts. \nPart 1: EASL MASH Innovation and Implementation Roadmap (10 February) brings together stakeholders to define implementation priorities and regulatory perspectives for MASH care across Europe. \nPart 2: Main Steatotic Liver Disease Summit Programme (11–13 February) is a three-day translational meeting that follows steatotic liver disease across its full continuum — from population policy to the patient in clinic\, and from tissue microenvironment to the single stressed hepatocyte and its organelles. \nAcross ten thematic sessions\, three State-of-the-Art lectures\, a dedicated best-abstract session\, and eight ePoster sessions\, the programme deliberately refuses to separate “basic” from “clinical.” The same disease spectrum — MASLD\, MetALD and ALD — is interrogated at every scale by epidemiologists\, hepatologists\, pathologists\, and cell and mechano-biologists. \nThe premise is that SLD is now a public-health problem with unresolved mechanistic and methodological foundations. The Summit therefore pairs the field’s most pressing questions (Has renaming the disease changed anything? Can a liver stiffness score predict outcomes? Can we still justify placebo arms?) with the biological and mechanistic insights that will shape future answers. Designed for all stakeholders in the SLD community\, the Summit provides a comprehensive update on the latest evidence\, emerging data\, and key developments across the field. \n\n\n\n\n\n\n\n\n\n\nScope\n\n\nThe Summit covers steatotic liver disease across the entire metabolic–alcohol spectrum\, spanning epidemiology and health policy\, stigma and the patient voice\, nutrition across the life course\, diagnostics (histology\, digital/AI pathology\, elastography\, fibrosis biomarkers)\, the cellular and microenvironmental mechanisms of progression\, advanced/decompensated disease\, clinical-trial methodology\, and current and emerging therapeutics. \n\n\nLearning Objectives\n\n\nOn completion\, participants should be able to: \n\nAppraise the practical impact of the WHO resolution and the SLD nomenclature change on health systems\, stigma and case-finding across specialties.\nIntegrate multidisciplinary management of patients with SLD.\nIntegrate nutritional assessment and intervention into SLD care across subtypes and generations\, including AUD and adolescent populations.\nCritically evaluate diagnostic tools — biopsy\, AI-assisted histology\, 3D tissue mapping\, vibration-controlled and shear-wave elastography\, and serum fibrosis markers — for their real prognostic and monitoring value.\nDifferentiate the cellular and microenvironmental mechanisms (macrophage niches\, matrix stiffness\, organelle crosstalk\, hepatocyte heterogeneity\, mitochondrial signaling) that drive SLD progression.\nApply current management principles for advanced SLD\, including portal hypertension\, prevention of decompensation and re-compensation\, and the role of bariatric surgery.\nAnalyse the methodological challenges of MASH trials — placebo arms\, screen failure\, non-response — and interpret responder definitions.\nSummarise approved and pipeline therapies for MASH and ALD\, and the complex problem of treating MetALD.\n\n\n\nTop reasons to attend\n\n\n\n\nTo receive a comprehensive update on the latest scientific\, clinical\, and translational developments in Steatotic Liver Disease\, including MASLD\, MetALD\, and ALD.\nTo engage in thought-provoking discussions with international experts on the evolving landscape of SLD—from public health to precision diagnostics and emerging therapies.\nTo present your research\, gain valuable feedback\, and connect with peers and mentors who can inspire your next career steps.\nTo meet and learn from Key Opinion Leaders shaping the future of SLD research\, clinical care\, and policy worldwide.
URL:https://globalliver.org/event/easl-steatotic-liver-disease-summit-2027-berlin/
CATEGORIES:Partner Event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270218
DTEND;VALUE=DATE:20270221
DTSTAMP:20261027T192759Z
CREATED:20261027T192759Z
LAST-MODIFIED:20261027T192759Z
UID:1486-1802908800-1803167999@globalliver.org
SUMMARY:HCC-LIVE - Chula Vista\, CA
DESCRIPTION:The HCC-LIVE 2027 Conference is scheduled for Thursday\, February 18\, through Saturday\, February 20\, 2027\, at the Gaylord Pacific Resort and Convention Center located in Chula Vista\, California.\n\n\nEvent Details\n\n\nDates: Thursday\, February 18 – Saturday\, February 20\, 2027\n\n\n\n\nLocation: Gaylord Pacific Resort and Convention Center (Chula Vista\, CA)\n\n\n\n\nFocus: Multidisciplinary medical discussions\, clinical updates\, and networking centered around hepatocellular carcinoma (HCC) and liver disease management\, with strong participation from interventional radiology and related specialties.
URL:https://globalliver.org/event/hcc-live-chula-vista-ca/
CATEGORIES:Partner Event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270302
DTEND;VALUE=DATE:20270305
DTSTAMP:20261027T192916Z
CREATED:20261027T192916Z
LAST-MODIFIED:20261027T192916Z
UID:1488-1803945600-1804204799@globalliver.org
SUMMARY:RARE Disease Week
DESCRIPTION:This free\, multi-day event brings together rare disease advocates from across the country to make their voices heard with their Members of Congress. #RareDC2027 \nSave the Date: March 2 – 4\, 2027\nRare Disease Week Registration will open on January 6\, 2027. \nThis free multi-day event\, hosted by the RARE Advocates\, a program of the RARE Foundation\, brings together rare disease advocates from across the country to make their voices heard with their Members of Congress. Participants are educated on policy proposals impacting the rare disease community and provided opportunities to advocate directly for policy change with their Members of Congress.\n#RareDC2027
URL:https://globalliver.org/event/rare-disease-week/
CATEGORIES:GLI Event,Partner Event
END:VEVENT
END:VCALENDAR